Europe — EMA
Otulfi (Ustekinumab)
GNH USA supplies Otulfi (Ustekinumab), a interleukin-12/23 inhibitor for plaque psoriasis, psoriotic
Request sourcing
What is Ustekinumab?
Ustekinumab, the active ingredient in Otulfi, is an interleukin‑12/23 inhibitor presented as a unknown strength/unknown form for intravenous use. It treats moderate to severe plaque psoriasis, psoriatic arthritis and Crohn’s disease in adults.
GNH USA supplies Otulfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Ustekinumab used for?
Otulfi is a monoclonal antibody that targets key cytokines involved in several immune‑mediated disorders.
- Plaque psoriasis: reduces skin lesions and improves quality of life. - Psoriatic arthritis: alleviates joint inflammation and slows disease progression. - Crohn’s disease: induces remission and maintains symptom control.
What are the side effects of Ustekinumab?
Adverse reactions to ustekinumab vary in frequency and severity.
Common Side Effects: - Upper respiratory tract infection - Headache - Fatigue - Nausea - Injection site pain - Diarrhea
Serious or Rare Side Effects: - Serious infections - Malignancy risk - Hypersensitivity reactions - Cardiovascular events - New onset or worsening inflammatory bowel disease - Neurological disorders such as demyelination.
What precautions apply to Ustekinumab?
When using Otulfi, clinicians should consider several safety aspects before and during therapy.
- Infection risk: assess and treat existing infections before starting. - Vaccination: update immunizations prior to initiation. - Monitoring: conduct regular laboratory tests to track blood counts and liver function. - Pregnancy and lactation: weigh potential benefits against risks; data are limited. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Ustekinumab interact with?
Ustekinumab may interact with other therapies that affect immune function.
Major Interactions (Avoid): - Live vaccines: contraindicated during treatment. - Strong immunosuppressants: may increase infection risk.
Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may augment immunosuppression. - Antifungal agents (azoles) that affect cytokine pathways. - Antiviral medications used for chronic infections. - Immunomodulatory biologics: combined use requires careful monitoring.
